Latest Ulcerative colitis Stories

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-02-13 16:25:08

NEW YORK, Feb. 13, 2014 /PRNewswire/ -- The CementBloc won a total of 69 major awards in 2013, cementing its status as the most-awarded healthcare agency in the United States. The CementBloc pulled in 4 CLIO Healthcare Awards (including its first-ever Gold CLIO); 11 Global Awards; 8 IPA Best of Health Awards; 5 MM&M Awards; 3 PM360 Pharma Choice Awards; 2 Manny Awards; and 36 Rx Club Awards. It was the best-ever showing in the agency's 13 years, and a significantly higher total than any...

2014-01-29 16:29:03

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q8l6jf/lexicons) has announced the addition of the "Lexicon's telotristat - A new approach to carcinoid syndrome" [http://www.researchandmarkets.com/research/q8l6jf/lexicons ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Lexicon is developing telotristat as therapy for carcinoid syndrome, an orphan' disease that occurs...

2014-01-29 12:27:38

OKLAHOMA CITY, Jan. 29, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in...

2014-01-09 08:28:44

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April. (Logo: http://photos.prnewswire.com/prnh/20140109/DA43446LOGO) "Positive ZA201...

2014-01-07 04:21:03

LONDON, January 7, 2014 /PRNewswire/ -- ~ ST10 strongly demonstrates potential to be (1) the only effective oral treatment for ferrous intolerant IDA patients and (2) an effective alternative to intravenous iron treatment ~ Shield Therapeutics (Shield), an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from...

Word of the Day
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'